HLS THERAPEUTICS INC (HLS.CA) Stock Fundamental Analysis
Canada - TSX:HLS - CA40390B1094 - Common Stock
5.59 CAD
-0.11 (-1.93%)
Taking everything into account, HLS scores 3 out of 10 in our fundamental rating. HLS was compared to 35 industry peers in the Pharmaceuticals industry. HLS has a bad profitability rating. Also its financial health evaluation is rather negative. HLS has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year HLS has reported negative net income.
HLS had a positive operating cash flow in the past year.
In the past 5 years HLS always reported negative net income.
Each year in the past 5 years HLS had a positive operating cash flow.
1.2 Ratios
HLS has a Return On Assets of -10.09%. This is in the lower half of the industry: HLS underperforms 60.00% of its industry peers.
HLS's Return On Equity of -22.60% is in line compared to the rest of the industry. HLS outperforms 48.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.09% | ||
| ROE | -22.6% | ||
| ROIC | N/A |
ROA(3y)-11.74%
ROA(5y)-9%
ROE(3y)-24.86%
ROE(5y)-18.35%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
HLS's Gross Margin of 82.59% is amongst the best of the industry. HLS outperforms 100.00% of its industry peers.
In the last couple of years the Gross Margin of HLS has declined.
HLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 82.59% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.41%
GM growth 5Y-2.67%
2. Health
2.1 Basic Checks
HLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HLS has been reduced compared to 1 year ago.
Compared to 5 years ago, HLS has more shares outstanding
Compared to 1 year ago, HLS has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -0.70, we must say that HLS is in the distress zone and has some risk of bankruptcy.
HLS has a Altman-Z score of -0.70. This is comparable to the rest of the industry: HLS outperforms 48.57% of its industry peers.
The Debt to FCF ratio of HLS is 4.74, which is a neutral value as it means it would take HLS, 4.74 years of fcf income to pay off all of its debts.
HLS has a better Debt to FCF ratio (4.74) than 80.00% of its industry peers.
HLS has a Debt/Equity ratio of 0.74. This is a neutral value indicating HLS is somewhat dependend on debt financing.
HLS's Debt to Equity ratio of 0.74 is on the low side compared to the rest of the industry. HLS is outperformed by 68.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.74 | ||
| Debt/FCF | 4.74 | ||
| Altman-Z | -0.7 |
ROIC/WACCN/A
WACC8.88%
2.3 Liquidity
A Current Ratio of 1.09 indicates that HLS should not have too much problems paying its short term obligations.
HLS has a worse Current ratio (1.09) than 74.29% of its industry peers.
A Quick Ratio of 0.84 indicates that HLS may have some problems paying its short term obligations.
HLS's Quick ratio of 0.84 is on the low side compared to the rest of the industry. HLS is outperformed by 68.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.09 | ||
| Quick Ratio | 0.84 |
3. Growth
3.1 Past
HLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.00%, which is quite impressive.
Looking at the last year, HLS shows a decrease in Revenue. The Revenue has decreased by -4.20% in the last year.
HLS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.88% yearly.
EPS 1Y (TTM)36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)-4.2%
Revenue growth 3Y-1.91%
Revenue growth 5Y0.88%
Sales Q2Q%-2.4%
3.2 Future
HLS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.68% yearly.
Based on estimates for the next years, HLS will show a small growth in Revenue. The Revenue will grow by 4.84% on average per year.
EPS Next Y46.24%
EPS Next 2Y31.47%
EPS Next 3Y21.75%
EPS Next 5Y16.68%
Revenue Next Year0.81%
Revenue Next 2Y5.6%
Revenue Next 3Y4.03%
Revenue Next 5Y4.84%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
HLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year HLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
HLS's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. HLS is cheaper than 71.43% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of HLS indicates a rather cheap valuation: HLS is cheaper than 82.86% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.78 | ||
| EV/EBITDA | 11.09 |
4.3 Compensation for Growth
A more expensive valuation may be justified as HLS's earnings are expected to grow with 21.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.47%
EPS Next 3Y21.75%
5. Dividend
5.1 Amount
HLS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:HLS (9/12/2025, 7:00:00 PM)
5.59
-0.11 (-1.93%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners45.35%
Inst Owner ChangeN/A
Ins Owners0.52%
Ins Owner ChangeN/A
Market Cap175.13M
Analysts77.78
Price Target6.83 (22.18%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-22.14%
Min EPS beat(2)-27.3%
Max EPS beat(2)-16.97%
EPS beat(4)0
Avg EPS beat(4)-14.64%
Min EPS beat(4)-27.3%
Max EPS beat(4)-2.42%
EPS beat(8)1
Avg EPS beat(8)-31.91%
EPS beat(12)1
Avg EPS beat(12)-51.17%
EPS beat(16)2
Avg EPS beat(16)-42.99%
Revenue beat(2)0
Avg Revenue beat(2)-1.71%
Min Revenue beat(2)-3.24%
Max Revenue beat(2)-0.17%
Revenue beat(4)0
Avg Revenue beat(4)-2.79%
Min Revenue beat(4)-5.77%
Max Revenue beat(4)-0.17%
Revenue beat(8)1
Avg Revenue beat(8)-4.15%
Revenue beat(12)2
Avg Revenue beat(12)-4.33%
Revenue beat(16)2
Avg Revenue beat(16)-5%
PT rev (1m)19.11%
PT rev (3m)19.11%
EPS NQ rev (1m)12.5%
EPS NQ rev (3m)5.41%
EPS NY rev (1m)-12.5%
EPS NY rev (3m)-12.5%
Revenue NQ rev (1m)-2.22%
Revenue NQ rev (3m)-3.86%
Revenue NY rev (1m)-0.49%
Revenue NY rev (3m)-0.25%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.24 | ||
| P/FCF | 10.78 | ||
| P/OCF | 9.84 | ||
| P/B | 1.9 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.09 |
EPS(TTM)-0.66
EYN/A
EPS(NY)-0.23
Fwd EYN/A
FCF(TTM)0.52
FCFY9.28%
OCF(TTM)0.57
OCFY10.16%
SpS2.49
BVpS2.94
TBVpS-2.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.09% | ||
| ROE | -22.6% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 82.59% | ||
| FCFM | 20.79% |
ROA(3y)-11.74%
ROA(5y)-9%
ROE(3y)-24.86%
ROE(5y)-18.35%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.41%
GM growth 5Y-2.67%
F-Score6
Asset Turnover0.38
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.74 | ||
| Debt/FCF | 4.74 | ||
| Debt/EBITDA | 3.23 | ||
| Cap/Depr | 5.15% | ||
| Cap/Sales | 1.99% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 83.94% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.09 | ||
| Quick Ratio | 0.84 | ||
| Altman-Z | -0.7 |
F-Score6
WACC8.88%
ROIC/WACCN/A
Cap/Depr(3y)0.36%
Cap/Depr(5y)20.34%
Cap/Sales(3y)0.19%
Cap/Sales(5y)11.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y46.24%
EPS Next 2Y31.47%
EPS Next 3Y21.75%
EPS Next 5Y16.68%
Revenue 1Y (TTM)-4.2%
Revenue growth 3Y-1.91%
Revenue growth 5Y0.88%
Sales Q2Q%-2.4%
Revenue Next Year0.81%
Revenue Next 2Y5.6%
Revenue Next 3Y4.03%
Revenue Next 5Y4.84%
EBIT growth 1Y44.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year287.73%
EBIT Next 3Y66.38%
EBIT Next 5Y37.49%
FCF growth 1Y-17.32%
FCF growth 3Y-20.24%
FCF growth 5Y-19.65%
OCF growth 1Y-10.49%
OCF growth 3Y-21.32%
OCF growth 5Y-21.24%